Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001213900-25-022364·Fairmount Funds Management LLC
Schedule 13D ownership disclosure
Oruka Therapeutics Inc
Common Stock, $0.001 par value · CUSIP: 687604108
Event date: 2025-03-06
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Fairmount Funds Management LLCReported CIK 0001802528
Shares: 8,511,824.00 · Class: 19.99%
- Fairmount Healthcare Fund II L.P.Reported CIK 0001769651
Shares: 5,938,516.00 · Class: 13.95%
- Fairmount Healthcare Co-Invest III L.P.Reported CIK 0002009690
Shares: 2,573,308.00 · Class: 6.87%
- Peter Evan HarwinReported CIK 0001663607
Shares: 8,511,824.00 · Class: 19.99%
- Tomas KiselakReported CIK 0001830177
Shares: 8,511,824.00 · Class: 19.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-022364
- Form type
- SCHEDULE 13D/A
- Filer
- Fairmount Funds Management LLC
- CIK
- CIK 1802528
- Filed
- Mar 10, 2025
- Reporting period
- Mar 06, 2025
- Description
- Schedule 13D beneficial ownership